Novo Nordisk increased operating profit by 34% in the first nine months of 2012
31 October 2012 | By Novo Nordisk
Sales grew 18% driven by Victoza®, NovoRapid® and Levemir®...
List view / Grid view
News
Roche medicine Avastin receives EU approval for the treatment of women with recurrent, platinum-sensitive ovarian cancer
31 October 2012 | By Roche
The EC has approved Avastin...
Novartis to start construction of new biotechnology facility in Singapore with an investment of over USD 500 million
31 October 2012 | By Novartis
Novartis announced the construction of a new state-of-the-art biotechnology production site...
Boehringer Ingelheim presents robust pipeline highlighting its Respiratory R&D
31 October 2012 | By Boehringer Ingelheim
Patients and physicians may have several innovative respiratory treatments available in the coming years...
Alzheimer’s, cancer and rare disease research to benefit from landmark MRC-AstraZeneca compound collaboration
31 October 2012 | By AstraZeneca
Funding for 15 research projects...
Genzyme announces publication of LEMTRADA (alemtuzumab) pivotal studies in The Lancet
31 October 2012 | By
Significant effects of LEMTRADA™ vs. Rebif ® described in CARE-MS I and CARE-MS II publications...
Gilead’s once-daily novel prodrug for the treatment of HIV meets 24-week primary objective in Phase 2 study
31 October 2012 | By Gilead Sciences
Data support tenofovir alafenamide fumarate as component of future single tablet HIV regimens...
Health Canada and Swissmedic lift precautionary holds on Novartis seasonal influenza vaccines
31 October 2012 | By Novartis
Novartis welcomes the decisions by Health Canada and Swiss Agency for Therapeutic Products, Swissmedic...
Biogen Idec and Sobi announce positive top-line results from Phase 3 study investigating long-lasting recombinant Factor VIII Fc fusion protein in Hemophilia A
31 October 2012 | By Biogen Idec
Biogen Idec and Swedish Orphan Biovitrum announced positive results from A-LONG...
Tecan and TAP Biosystems to automate RAFT™ 3D cell culturing on the Freedom EVO®
30 October 2012 | By kdm communications limited
Tecan and TAP Biosystems, a leading supplier of innovative cell culture systems, have announced a co-marketing agreement to further expand the automated 3D cell culture capabilities of the Freedom EVO® liquid handling platform. Automation of TAP’s collagen-based RAFT™ cell culture system will allow scientists to quickly and conveniently create 3D…
GSK announces start of Phase lll programme for mepolizumab in severe refractory asthma
30 October 2012 | By GlaxoSmithKline
GlaxoSmithKline announced the start of a Phase III programme...
Abbott introduces Ensure Complete™ shakes for adults
30 October 2012 | By Abbott
Ensure Complete combines muscle, heart, immune system and bone benefits in one simple shake...
Drugs of abuse screening benefits from LoGiCal® reference materials
29 October 2012 | By kdm communications limited
Unilabs AB in Eskilstuna, Sweden, is taking advantage of LGC Standards’ LoGiCal reference materials...
Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio
29 October 2012 | By GlaxoSmithKline
ViiV Healthcare Ltd and Shionogi & Co., Ltd., have entered into an agreement...
European approval granted for Trajenta® (linagliptin) tablets
26 October 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company today announced that the European Commission has approved an expanded therapeutic indication for the DPP-4 inhibitor Trajenta® (linagliptin) to include use in combination with insulin in adults with Type 2 Diabetes.
